PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021
February 24 2021 - 4:15PM
Business Wire
Guest speakers Include Deepak Bhatt, MD,
MPH and John Fanikos, RPh, MBA
Presentations from PhaseBio Leadership Team
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiopulmonary diseases,
today announced that it will host a virtual Investor and Analyst
Day on March 15, 2021 from 12:00 p.m. to 2:00 p.m. ET. The event
will focus on an overview of the bentracimab development program,
including current enrollment status for the ongoing global Phase 3
REVERSE-IT trial. Bentracimab is a novel, human monoclonal antibody
fragment that in earlier trials has shown immediate and sustained
reversal of the antiplatelet effects of Brilinta® (ticagrelor).
Presenters Include:
- Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, Executive
Director of Interventional Cardiovascular Programs, Brigham and
Women's Hospital Heart & Vascular Center and Professor of
Medicine at Harvard Medical School
- John Fanikos, RPh, MBA, Director of Pharmacy Business and
Financial Services, Brigham and Women’s Hospital
- Jonathan Mow, Chief Executive Officer, PhaseBio
- John Lee, MD, Chief Medical Officer, PhaseBio
- Susan Arnold, PhD, Vice President, Preclinical & CMC,
PhaseBio
- Lauren Richardson, Global Head, Regulatory Affairs and Quality
Assurance, PhaseBio
- Michael York, Vice President, Corporate Development &
Commercial Strategy, PhaseBio
The presentations will be followed by Q&A with the PhaseBio
management team and guest speakers.
Video Webcast and Replay
A live video webcast will be streamed along with accompanying
slides. Interested parties may RSVP to join the virtual event
through the following registration link:
http://wsw.com/webcast/cc/phas
A webcast replay of the event and slides will be available for
30 days on the Events & Presentations page of the “Investors”
section of the company’s website at www.phasebio.com.
About Bentracimab (PB2452)
Bentracimab is a novel, recombinant, human monoclonal antibody
antigen-binding fragment designed to reverse the antiplatelet
activity of ticagrelor in major bleeding and urgent surgery
situations. In a Phase 1 clinical trial, bentracimab demonstrated
the potential to bring life-saving therapeutic benefit through
immediate and sustained reversal of ticagrelor’s antiplatelet
activity, mitigating concerns regarding bleeding risks associated
with the use of this antiplatelet drug. The Phase 1 clinical trial
of bentracimab in healthy volunteers was published in the New
England Journal of Medicine in March 2019. In April 2019,
bentracimab received Breakthrough Therapy Designation from the Food
and Drug Administration (FDA). Breakthrough Therapy Designation may
be granted by the FDA when preliminary clinical evidence indicates
that the drug may demonstrate substantial improvement over existing
therapy. In September 2019, PhaseBio completed a Phase 2a trial in
which bentracimab was investigated in older and elderly subjects on
dual antiplatelet therapy of ticagrelor and low-dose aspirin.
Additionally, the Phase 2a trial investigated a bentracimab regimen
for the reversal of supratherapeutic doses of ticagrelor in healthy
younger subjects. In both arms of the trial, bentracimab achieved
immediate and sustained reversal of the antiplatelet effects of
ticagrelor and was generally well-tolerated, with only minor
adverse events reported. These results are consistent with the
results observed in healthy younger subjects treated with
ticagrelor in the previously published Phase 1 trial. PhaseBio
initiated the REVERSE-IT trial, a pivotal Phase 3 clinical trial of
bentracimab, in March 2020 to support a Biologics License
Application for bentracimab in both major bleeding and urgent
surgery indications. There are currently no approved reversal
agents for ticagrelor or any other antiplatelet drugs.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiovascular and
cardiopulmonary diseases. The company’s pipeline includes:
bentracimab (PB2452), a novel reversal agent for the antiplatelet
therapy ticagrelor; pemziviptadil (PB1046), a once-weekly
vasoactive intestinal peptide receptor agonist for the treatment of
pulmonary arterial hypertension; and PB6440, an oral agent for the
treatment of resistant hypertension. PhaseBio’s proprietary
elastin-like polypeptide technology platform enables the
development of therapies with potential for less-frequent dosing
and improved pharmacokinetics, including pemziviptadil, and drives
both internal and partnership drug-development opportunities.
PhaseBio is located in Malvern, PA, and San Diego, CA. For more
information, please visit www.phasebio.com, and follow us on
Twitter @PhaseBio and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “anticipates,” “believes,” “expects,”
“intends,” “projects,” and “future” or similar expressions are
intended to identify forward-looking statements.
Forward-looking statements include statements concerning or
implying the conduct or timing of our clinical trials and our
research, development and regulatory plans for our product
candidates, the potential for these product candidates to receive
regulatory approval from the FDA or equivalent foreign regulatory
agencies, and whether, if approved, these product candidates will
be successfully distributed and marketed. Forward-looking
statements are based on management's current expectations and are
subject to various risks and uncertainties that could cause actual
results to differ materially and adversely from those expressed or
implied by such forward-looking statements. Accordingly, these
forward-looking statements do not constitute guarantees of future
performance, and you are cautioned not to place undue reliance on
these forward-looking statements. Risks regarding our business are
described in detail in our Securities and Exchange Commission
(“SEC”) filings, including in our Quarterly Report on Form 10-Q for
the quarter ended September 30, 2020. These forward-looking
statements speak only as of the date hereof, and PhaseBio
Pharmaceuticals, Inc. disclaims any obligation to update these
statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210224006077/en/
Investor Contact: John Sharp PhaseBio Pharmaceuticals,
Inc. Chief Financial Officer (610) 981-6506
john.sharp@phasebio.com
Media Contact: Will Zasadny Canale Communications, Inc.
will.zasadny@canalecomm.com (619) 961-8848
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Mar 2024 to Apr 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Apr 2023 to Apr 2024